Patentability Of Frontline Plus Formulation Claims Confirmed
Merial announced today the United States Patent and Trademark Office reconfirmed the patentability of formulation claims covering Merial’s Frontline Plus, a flea and tick control product.
“The ultimate result is that we expect some of the products infringing the formulation claims to be removed from the market.” says Judy Jarecki-Black, PhD, Esq., head of intellectual property with Merial, an animal health pharmaceutical company.
Additional information regarding companies involved with potential formulation infringement and actionable steps was expected to be released later this week, according to earlier information from a public relations representative. The release of the additional information is now expeted in coming weeks, according to Merial.
“We are pleased that the patent office confirmed the patentability of Merial’s inventions directed at fipronil and (S)-methoprene containing spot-on compositions,” Dr. Jarecki-Black says. “Merial is also pursuing litigation against other manufacturers in cases where it believes its patents have been violated. We plan to continue to vigorously defend our patent rights and continue our strong support of the veterinary profession.”